Imagine Pharma LLC

Imagine Pharmaceuticals, Inc. is a US-based biotechnology company focused on innovative drug delivery systems and therapeutic solutions. They aim to improve patient outcomes through advanced medical technologies. Imagine Pharmaceuticals, Inc.

specializes in the development of innovative biopharmaceutical solutions. Founded in 2004 and headquartered in Pittsburgh, US, the company has since conducted three investment deals. The most recent funding round, a Series A, occurred on October 31, 2023, led by IP Investors LLC, raising USD 32. 5 mn.

The company was founded by Ngoc Thai and is currently led by CEO Santiago Pujadas. Imagine Pharma specializes in three innovative platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, centered around their novel polypeptide, IMG-1. Their Oral Delivery platform utilizes a proprietary natural delivery system for biologic drugs traditionally administered by injection, enhancing patient compliance. The Therapeutics platform focuses on developing treatments for various disease states, while the Regenerative Medicine platform promotes the propagation of critical body cell types, addressing conditions requiring cellular regeneration.

Their products target healthcare institutions and providers in pediatric care, chronic disease management, and advanced wound care across North America and Europe. Imagine Pharma operates through partnerships with healthcare institutions for distributing its therapies and may also employ direct-to-consumer approaches for its Oral Delivery products. Revenue streams are expected to come from collaborations with hospitals and clinics, particularly in islet transplantation and other therapies, potentially involving performance-based agreements. Licensing fees for proprietary technologies and collaboration agreements for co-development of therapeutics may also contribute to their revenue.

The company’s flagship offerings are positioned to command premium pricing reflective of their advanced treatment capabilities. Following the Series A funding round led by IP Investors LLC in October 2023, Imagine Pharma will utilize the USD 32. 5 mn to accelerate pre-clinical studies and commercialization of its products. The company aims to launch new products focused on innovative therapeutic solutions and expand its market reach into new geographic regions.

Specific target markets for expansion include additional healthcare institutions in North America and Europe, with plans to enhance their distribution capabilities in these areas.